Retatrutide vs tirzepatide: which fits the research question?
Tirzepatide activates two receptors, GIP and GLP-1. Retatrutide activates those two plus the glucagon receptor. Choose tirzepatide for questions about dual incretin signalling, insulin secretion and appetite; choose retatrutide when the question involves energy expenditure, hepatic fat or the glucagon pathway. Both are lyophilized, lot-tested and sold for laboratory research only.
| Retatrutide | Tirzepatide | |
|---|---|---|
| Receptors | GIP, GLP-1, glucagon | GIP, GLP-1 |
| Length | 39 amino acids | 39 amino acids |
| Backbone | Glucagon-derived | GIP-derived |
| Side chain | C20 fatty diacid | C20 fatty diacid |
| Distinguishing pathway | Glucagon receptor: energy expenditure, hepatic lipid | GIP receptor bias: insulin potentiation, adipose |
| Typical research use | Triple-agonist comparisons, expenditure models | Dual-incretin reference compound |
| Key clinical context | Phase 2, NEJM 2023 | SURMOUNT-1, NEJM 2022 |
| Current lot purity | 99.4% (RT-2609-A) | 99.2% (TZ-2608-C) |
| Vial | 10 mg, $105 | 10 mg, $120 |
What does the glucagon receptor add?
Glucagon receptor activation raises energy expenditure and hepatic fat oxidation, effects the incretin receptors do not produce on their own. On its own it also raises blood glucose, which is why a triple agonist has to balance the glucagon component against the incretin components. Studies that measure expenditure by indirect calorimetry, or hepatic lipid content, are the ones where retatrutide's extra receptor matters.
When is tirzepatide the better choice?
When the question is about the incretin pathways themselves. Tirzepatide's GIP receptor bias is a research topic in its own right, and its larger published dataset makes it the cleaner comparator for GLP-1-only compounds like semaglutide. Adding a glucagon arm would confound an incretin question.
Can they be run side by side?
Yes, and that is the most common design. The Metabolic trio bundle ships retatrutide, tirzepatide and semaglutide as three lot-matched vials with three certificates, so a three-arm comparison starts from verified material.
Common questions
Is retatrutide just tirzepatide with an extra receptor?
Functionally that is the difference in receptor coverage, but they are distinct 39-residue sequences with different backbones — retatrutide is glucagon-derived, tirzepatide GIP-derived. They are not the same molecule with an addition.
Which one should a metabolic study use?
It depends on what the design needs to attribute. Tirzepatide isolates incretin signalling; retatrutide adds glucagon receptor activity, so an effect seen only with retatrutide points at that third pathway.
Where to go next
- Retatrutide research guide · Retatrutide product page
- Tirzepatide research guide · Tirzepatide product page
For laboratory research use only. Clinical trial results are cited as context and do not describe use of the material sold here.
